Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.37 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469159 | 1.00 | LPL (0.37) | LPLLIPGBCAT1ESR2TSHR | |
| SCHEMBL15026275 | 0.82 | LPL (0.46) | LPLLIPGJAK2BTK | |
| SCHEMBL12365297 | 0.82 | TSHR (0.46) | LPLLIPGESR2TSHR | |
| SCHEMBL31200765 | 0.81 | DYRK1A (0.35) | LPLLIPGESR2TSHRJAK2 | |
| SCHEMBL20605570 | 0.81 | LPL (0.37) | LPLLIPGESR2TRPV4 | |
| SCHEMBL25309188 | 0.80 | LPL (0.34) | LPLLIPGTSHRJAK2BTK | |
| SCHEMBL12389605 | 0.78 | POLB (0.40) | TSHR | |
| SCHEMBL21458742 | 0.78 | LIPG (0.40) | LPLLIPGJAK2BTK | |
| SCHEMBL31483909 | 0.78 | LIPG (0.40) | LPLLIPGJAK2BTK | |
| SCHEMBL29616950 | 0.77 | LPL (0.37) | LPLLIPGBCAT1ESR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-12466815-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| US-20240150326-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| CN-112292380-B | N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for the treatment of cancer | 因赛特公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20240083913-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2024-03-14 | — | — | US | disclosed |
| US-20240043448-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2024-02-08 | — | — | US | disclosed |
| EP-1532136-A1 | PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | disclosed |
| EP-1511748-A1 | 8-FLUORIMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-03-09 | — | — | EP | disclosed |
| EP-1511747-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-03-09 | — | — | EP | disclosed |
| EP-1504007-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-02-09 | — | — | EP | disclosed |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | MERCK SHARP & DOHME, LTD. (GB) | 2004-09-30 | — | — | US | disclosed |
| WO-2004076452-A1 | 5,8-DIFLUOROIMIDAZO[1,2-a]PYRIDINES AS GABA-A α2/α3 LIGANDS FOR TREATING ANXIETY AND/OR DEPRESSION | MERCK SHARP & DOHME LIMITED (GB) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004014891-A1 | PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003099817-A1 | 8-FLUORIMIDAZO`1,2-A!PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099816-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003093272-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | LPL 2624/4885LIPG 2348/4885BCAT1 4212/4885 |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | YAP1, TEAD3, TEAD2 | LPL 2345/4885LIPG 2795/4885BCAT1 160/4885 |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | LPL 2345/4885LIPG 2795/4885BCAT1 160/4885 |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | GABRA1, GABRA5, GABRA2 | LPL 4762/4885LIPG 4876/4885BCAT1 482/4885 |
| US-20240150326-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | PCK1, PHKG2, PHKG1 | LPL 2908/4885LIPG 3259/4885BCAT1 1503/4885 |
| US-20240083913-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | KRAS, NRAS, HRAS | LPL 2624/4885LIPG 2348/4885BCAT1 4212/4885 |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | LPL 2624/4885LIPG 2348/4885BCAT1 4212/4885 |
| US-12466815-B2 | Carboxamide compounds and uses thereof | PCK1, PHKG2, PHKG1 | LPL 2908/4885LIPG 3259/4885BCAT1 1503/4885 |
| US-20240043448-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | KRAS, NRAS, HRAS | LPL 2624/4885LIPG 2348/4885BCAT1 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.